Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study describes a newly recognized skin reaction associated with dasatinib, nilotinib, and ponatinib, marked by a lichenoid exanthem with severe pruritus that may necessitate discontinuation of therapy.

This source reviews the common skin-related side effects of tyrosine kinase inhibitors in treating endocrine cancers and emphasizes that proactive, multidisciplinary management can effectively control these adverse events without compromising cancer treatment efficacy.

This study introduces ficlatuzumab, an anti-HGF monoclonal antibody, in combination with gefitinib in a phase 2 trial to address EGFR TKI resistance in Asian NSCLC patients.

In this study, Deplanque et al. (2016) explored doxycycline's role in preventing erlotinib-induced folliculitis in patients with non-small-cell lung cancer, highlighting skin toxicity as a common side effect that can affect patient adherence to treatment.

This case report documents new hair growth in a 57-year-old man with androgenic alopecia after receiving gefitinib treatment for non-small-cell lung cancer.

This article reviews drug-induced hair and nail disorders and discusses their clinical recognition, underlying mechanisms, and potential treatment strategies, without presenting new research findings.

This case report describes erosive pustular dermatosis of the scalp in a patient undergoing gefitinib treatment for lung cancer, and reviews literature on drug-induced cases of this rare condition.

This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.

This phase I study determined that a combination of oral SU-014813 and docetaxel is a feasible treatment with a manageable safety profile and potential anti-tumor activity, particularly noted in melanoma and GIST patients.

This report details a case of extensive leukotrichia induced by dasatinib in a patient with refractory chronic myelogenous leukemia.

This case report describes a rare instance of renal cell carcinoma metastasizing to the ovary and early onset of alopecia after beginning sunitinib treatment, though hypothyroidism and dandruff complicate attribution to the drug.

This review reported that certain systemic drugs, including antiepileptics and anticancer drugs, can lead to changes in hair pigmentation, such as hypopigmentation or hyperpigmentation, with varied prevalence and clinical characteristics.

In this report, two cases of non-small cell lung cancer treated with gefitinib showed unexpected hair growth, suggesting a potential new application of EGFR-TKIs for alopecia.

This review discusses the potential regulation of signal transduction pathways by microRNAs in animal cells, aiming to identify biological processes that may be influenced by miRNA-mediated regulation, but it reports no new experimental outcomes.

This case report highlights an instance of nilotinib-induced keratosis pilaris without alopecia or pruritus, emphasizing the need for awareness to optimize patient outcomes.

This study examined the FDA Adverse Events Reporting System and found new dermatologic adverse events associated with EGFR-TKIs in non-small cell lung cancer patients, such as specific skin, nail, and hair issues, that aren't currently listed on drug labels.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

This paper reviews recent advancements in understanding hair follicle structure and the role of JAKs in hair growth, though it does not report new experimental findings.

In this study, researchers focused on the "bulge region" of hair follicles, identifying Janus kinases as key players in hair growth signaling, which could inform new therapies for hair restoration.

This review discusses various therapeutic strategies targeting platelet-derived growth factor signaling in diseases like cancer and atherosclerosis, and evaluates existing treatments without presenting new clinical data.

This review discusses common cutaneous reactions to targeted cancer drugs such as tyrosine kinase inhibitors and reports no new clinical results.

This case report documents a 61-year-old woman treated with erlotinib who experienced the rare side effect of cicatricial alopecia.

This case study describes a 33-year-old woman with chronic myelogenous leukemia who developed nonscarring alopecia after starting nilotinib therapy, linked to perifollicular inflammation.

This case report describes a patient who experienced rapid hair depigmentation after starting pazopanib for metastatic renal cell carcinoma, which may suggest therapy success despite being distressing.

This report describes a rare case of a non-small-cell lung cancer patient experiencing hair changes after prolonged gefitinib treatment, potentially linked to EGFR inhibition, with limited understanding of its cause.

A new gene mutation may allow some piebaldism patients to regain skin color in white patches.

This case study reports generalized keratosis pilaris as a rare cutaneous side effect of nilotinib in a 40-year-old woman with chronic myeloid leukemia, highlighting the need for awareness among physicians.

This review highlights Ritlecitinib as a promising new oral treatment for Alopecia Areata, emphasizing its targeted action and potential efficacy, especially in adults and adolescents, though it notes the need for further real-world effectiveness and long-term safety studies.

This article reviews skin toxicity classifications and management in patients undergoing molecularly targeted therapy, noting significant dermatotropic side effects associated with Epidermal Growth Factor Receptor Inhibitors.

This study reported a rare case of pityriasis rubra pilaris-like skin reaction in an 18-year-old woman after starting ponatinib treatment for relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia, which resolved after treatment adjustment and did not recur over 15 months.